<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175694</url>
  </required_header>
  <id_info>
    <org_study_id>Brachy-APBI-03</org_study_id>
    <nct_id>NCT01175694</nct_id>
  </id_info>
  <brief_title>Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer</brief_title>
  <official_title>Phase II Study - Dose Optimization PDR/HDR Brachytherapy Alone for Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Erlangen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accelerated partial breast irradiation (APBI) leads to a equivalent local control rate with&#xD;
      lower toxicity as external beam irradiation (EBI) after breast conserving surgery (BCS) in a&#xD;
      highly selected subgroup of patients with low risk invasive carcinoma and low risk duct&#xD;
      carcinoma in-situ (DCIS). The goal of this trial is to assess the role of a modified dose of&#xD;
      pulsed-dose-rate (PDR) and high-dose-rate (HDR) brachytherapy alone as Accelerated Partial&#xD;
      Breast Irradiation (APBI) in a defined low-risk group of invasive breast cancer or ductal&#xD;
      carcinoma in situ concerning local failure (all ipsilateral local recurrences), in particular&#xD;
      regarding the local recurrences, the toxicity and for the cosmetic result. It is a phase II&#xD;
      study. According to study protocol altogether 200 female patients will be treated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Focus of this trial is to assess the role a modified dose of PDR- and HDR-brachytherapy as&#xD;
      Accelerated Partial Breast Irradiation (APBI) alone in a defined low-risk group of invasive&#xD;
      breast cancer or ductal carcinoma in situ concerning local failure(all ipsilateral local&#xD;
      recurrences, in particular regarding the local recurrences, the toxicity and for the cosmetic&#xD;
      result.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local control rates</measure>
    <time_frame>five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>late side effects</measure>
    <time_frame>5 years</time_frame>
    <description>to assess the incidence and severity of acute and late side effects of brachytherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Brachytherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interstitial multicatheter brachytherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Interstitial multicatheter brachytherapy</intervention_name>
    <description>Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq</description>
    <arm_group_label>Brachytherapy</arm_group_label>
    <other_name>APBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Stage 0, I or II breast cancer.&#xD;
&#xD;
          -  Invasive ductal, papillary, mucinous, tubular, medullary or lobular carcinoma.&#xD;
&#xD;
          -  Ductal carcinoma in situ (DCIS) alone.&#xD;
&#xD;
          -  No lymph invasion (L0) and no hemangiosis (V0).&#xD;
&#xD;
          -  Lesions of &lt; 3 cm diameter, histopathologically assured.&#xD;
&#xD;
          -  pN0 (a minimum of 6 nodes in specimen, or a negative sentinel node is acceptable).&#xD;
&#xD;
          -  M0.&#xD;
&#xD;
          -  Clear resection margins at least 2 mm in any direction; by lobular histology or DCIS&#xD;
             histology only the resection margins must be clear at least 5 mm.&#xD;
&#xD;
          -  For DCIS only: lesions must be classified as low or intermediate risk group&#xD;
&#xD;
          -  Unifocal and unicentric DCIS or breast cancer.&#xD;
&#xD;
          -  Age &gt; 50 years.&#xD;
&#xD;
          -  Time interval from final definitive breast surgical procedure to the start of external&#xD;
             beam therapy or to brachytherapy is less than 12 weeks (84 days). If patients receive&#xD;
             chemotherapy the radiotherapy can be started before systemic treatment (within 12&#xD;
             weeks). The radiation therapy can be also given in the interval between the&#xD;
             chemotherapy courses. It is also possible to start radiation therapy after&#xD;
             chemotherapy is completed according local protocols as soon as possible within 4 weeks&#xD;
             after chemotherapy.&#xD;
&#xD;
          -  Signed study-specific consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage III or IV breast cancer.&#xD;
&#xD;
          -  Surgical margins that cannot be microscopically assessed.&#xD;
&#xD;
          -  Extensive intraductal component (EIC).&#xD;
&#xD;
          -  Paget's disease or pathological skin involvement.&#xD;
&#xD;
          -  Synchronous or previous breast cancer.&#xD;
&#xD;
          -  Prior malignancy (&lt; 5 years prior to enrollment in study) except non-melanoma skin&#xD;
             cancer or cervical carcinoma International Federation of Gynecology and Obstetrics&#xD;
             (FIGO) 0 and I if patient is continuously disease-free.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Collagen vascular disease.&#xD;
&#xD;
          -  The presence of congenital diseases with increased radiation sensitivity, for example&#xD;
             Ataxia telangiectatic or similar.&#xD;
&#xD;
          -  Psychiatric disorders.&#xD;
&#xD;
          -  Patient with breast deemed technically unsatisfactory for brachytherapy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vratislav Strnad, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vratislav Strnad, MD, Prof.</last_name>
    <phone>49 9131 8544205</phone>
    <email>vratislav.strnad@uk-erlangen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of Radiation Oncology, University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vratislav Strnad, MD, Prof.</last_name>
      <phone>49 9131 8544205</phone>
      <email>vratislav.strnad@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Godehard Lahmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2010</study_first_posted>
  <last_update_submitted>August 19, 2010</last_update_submitted>
  <last_update_submitted_qc>August 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Vratislav Strnad, MD, Prof.</name_title>
    <organization>University Hospital Erlangen</organization>
  </responsible_party>
  <keyword>Brachytherapy</keyword>
  <keyword>APBI</keyword>
  <keyword>dose modification</keyword>
  <keyword>local recurrences</keyword>
  <keyword>side effects</keyword>
  <keyword>cosmetic result</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

